PTPN13 and chronic myelogenous leukemia, BCR-ABL1 positive: We found that Fap1 inhibition in a murine model of CML delayed emergence of TKI resistance and decreased LSC persistence in vivo, suggesting relevance of Icsbp/Fap1 regulated events [23].